Lupus pernio is a chronic, disfiguring form of cutaneous sarcoidosis involving the skin of the face and other areas. This specific presentation warrants a targeted therapeutic approach distinct from general sarcoidosis management.
This protocol applies to patients with sarcoidosis presenting with cutaneous involvement characterised by lupus pernio. Retrospective evidence indicates that this particular form of skin sarcoidosis responds differently to therapy than other sarcoidosis manifestations, supporting a specific treatment selection.
For lupus pernio, the structured protocol involves anti-TNF therapy — the specific agents, decision criteria, and complete regimen details are available in the full protocol.
For lupus pernio, a large retrospective study reported that anti-TNF therapy was significantly better than cytotoxic or antimalarial therapy, and it could be considered as second-line therapy for this particular form of skin sarcoidosis.
View source ↗